Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
| MarketCap | 9B |
|---|---|
| PE Ratio | -8.5 |
| PEG Ratio | 0.7 |
| P/B | 1.1 |
| P/S (ttm) | 0.7 |
| Earning Growth (QoQ) | 12% |
| Revenue Growth (QoQ) | |
| Short % | 0% |
| Held by Institutions % | 53% |
| 1 Day Vol Adjusted Return | 1.6 |
| 1 Month Vol Adjusted Return | -5.4 |
| 3 Month Vol Adjusted Return | 0.5 |
| 6 Month Vol Adjusted Return | -3.8 |
| 20 Days SMA Price ZScore | -0.9 |
| 50 Days SMA Price ZScore | -1.1 |
| 12 -26 Days PPO | -4.7 |
| 1 Month Average Short Volume Ratio | 49.5 |
| 1 Day Volume Change ZScore | 0.3 |
| 1 Month Daily Vol | 2.0 |
Stock news
Teva Pharmaceutical Industries (NYSE: TEVA) stock closed the trading week in style, rising by over 3% on a bleak and bearish day for the wider market. Teva Pharmaceuticals, the company's key subsidiary, has reached an agreement with the southern state's attorney general to settle accusations of price-fixing. Under the terms of the arrangement, Teva is to pay just under $3.35 million; in return, once the funds are handed over Georgia will dismiss all claims against the company in the case.
TEL AVIV, Israel & PARSIPPANY, N.J., September 30, 2022--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached an agreement with the Attorney General (AG) of Georgia to settle the state’s price-fixing claims against Teva. Teva will pay the state $3.346 million as part of the settlement, and the state will dismiss all of its claims against Teva and its affiliates once payment has been made.
Europe's drug makers have warned about stopping manufacturing some cheap generic medicines amid surging electricity costs. The generic drug industry lobby group, Medicines for Europe, representing Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Novartis AG's (NYSE: NVS) Sandoz unit, and Fresenius SE's (OTC: FSNUY) Kabi business, sent a letter to European states' energy and health ministers, asking for measures to relieve the cost burden. According to Medicines for Europe, Generic associations p
TEL AVIV, Israel & PARSIPPANY, N.J., September 26, 2022--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of the Honestly HD website, which aims to provide information, inspiration and resources to help people understand what to expect with Huntington’s Disease (HD) chorea – one of the most visible and treatable symptoms of HD – and, how to talk to their doctor about preserving independence. In addition to the newly l
To avert a collision of patents and safety regulations, the Supreme Court must ensure that a damaging ruling is quickly undone.
Reuters reported that Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) CEO said the company will finalize the U.S. opioid settlement by the end of 2022 and start paying in 2023. CEO Kare Schultz also said he was unlikely to renew his contract next year. In its Q2 earnings release, Teva proposed a $4.35 billion settlement - mostly cash and partly medicines over 13 years - to resolve its opioid lawsuits. Related: New York Attorney General Says Teva Tried To Evade Accountability On Opioid Crisis.
Teva Pharmaceutical Industries expects to finalise an opioid settlement in the United States by year-end and start paying in 2023, its chief executive said on Sunday, while confirming he was unlikely to renew his contract next year. After years of negotiations, Israel-based Teva in July proposed a $4.35 billion nationwide settlement - mostly cash and partly medicines that will amount to $300 million to $400 million over 13 years - to resolve its opioid lawsuits. CEO Kare Schultz said Teva was ...